帕博利珠单抗诱发的转移性食管腺癌患者中毒性表皮坏死松解症
Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
作者信息
Gallo Marin Benjamin, Oliva Rocío, Kahn Benjamin, Borgovan Theo, Brooks Blake Elizabeth, Massoud Cathy M
机构信息
Brown Dermatology, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
Division of Hematology and Oncology, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
出版信息
R I Med J (2013). 2022 Apr 1;105(3):34-36.
Abstract
Adverse cutaneous reactions associated with the immune checkpoint inhibitor (ICI) pembrolizumab are well documented, yet life-threatening reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are infrequent.1,2 We present a case of pembrolizumab-induced TEN in a patient with metastatic esophageal adenocarcinoma who was successfully treated with cyclosporine and systemic corticosteroids.
摘要
与免疫检查点抑制剂（ICI）帕博利珠单抗相关的皮肤不良反应已有充分记录，但诸如史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症（SJS/TEN）等危及生命的反应并不常见。1,2我们报告一例转移性食管腺癌患者发生帕博利珠单抗诱导的TEN，该患者通过环孢素和全身性皮质类固醇成功治愈。
相似文献
1
Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.帕博利珠单抗诱发的转移性食管腺癌患者中毒性表皮坏死松解症
R I Med J (2013). 2022 Apr 1;105(3):34-36.
2
Toxic epidermal necrolysis associated with pembrolizumab.与帕博利珠单抗相关的中毒性表皮坏死松解症。
J Oncol Pharm Pract. 2020 Jul;26(5):1259-1265. doi: 10.1177/1078155219890659. Epub 2019 Dec 6.
3
Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.免疫检查点抑制剂诱导的表皮坏死松解症：评估人口统计学、临床特征和罪魁祸首药物的叙述性综述。
J Dermatol. 2024 Jan;51(1):3-11. doi: 10.1111/1346-8138.17039. Epub 2023 Nov 30.
4
Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report.帕博利珠单抗致转移性宫颈鳞癌患者史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症 1 例报告
Am J Dermatopathol. 2020 Apr;42(4):292-296. doi: 10.1097/DAD.0000000000001527.
5
Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.帕博利珠单抗相关史蒂文斯-约翰逊综合征伴原发性肝细胞癌患者的角化不良。
Australas J Dermatol. 2022 Feb;63(1):e71-e74. doi: 10.1111/ajd.13704. Epub 2021 Aug 31.
6
Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review.史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症与免疫检查点抑制剂相关：系统评价。
Front Immunol. 2024 Jul 12;15:1414136. doi: 10.3389/fimmu.2024.1414136. eCollection 2024.
7
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.系统医学时代的史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症。
Methods Mol Biol. 2022;2486:37-54. doi: 10.1007/978-1-0716-2265-0_3.
8
Carbamazepine-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Treated Successfully with Oral Cyclosporin: Case report and literature review.口服环孢素成功治疗卡马西平诱导的史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症重叠综合征：病例报告及文献综述
Sultan Qaboos Univ Med J. 2021 Aug;21(3):491-494. doi: 10.18295/squmj.4.2021.002. Epub 2021 Aug 29.
9
Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.史蒂文斯-约翰逊综合征在帕博利珠单抗治疗过程后期出现。
J Oncol Pharm Pract. 2019 Sep;25(6):1520-1522. doi: 10.1177/1078155218791314. Epub 2018 Aug 7.
10
Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.史蒂文斯－约翰逊综合征和中毒性表皮坏死松解症——识别与管理的挑战
J Assoc Physicians India. 2000 Oct;48(10):999-1003.
引用本文的文献
1
Pembrolizumab-induced Stevens-Johnson syndrome-like reaction: An atypical clinical presentation.帕博利珠单抗诱发的史蒂文斯-约翰逊综合征样反应：一种非典型临床表现。
JAAD Case Rep. 2024 Oct 28;54:69-72. doi: 10.1016/j.jdcr.2024.10.004. eCollection 2024 Dec.
2
Severe Cutaneous Toxicity in A 67-Year-Old Patient with Metastatic Urothelial Carcinoma Undergoing Therapy with Enfortumab Vedotin and Pembrolizumab.一名67岁转移性尿路上皮癌患者在接受安维汀（Enfortumab Vedotin）和帕博利珠单抗治疗时出现严重皮肤毒性。
Eur J Case Rep Intern Med. 2024 Nov 28;11(12):005003. doi: 10.12890/2024_005003. eCollection 2024.
3
Superficial mucoceles as a sequel to Stevens‑Johnson syndrome during treatment of cutaneous squamous cell carcinoma with cemiplimab: A case report and review of literature.在使用西米普利单抗治疗皮肤鳞状细胞癌期间，史蒂文斯-约翰逊综合征继发浅表黏液囊肿：一例报告并文献复习
Exp Ther Med. 2024 Nov 18;29(1):15. doi: 10.3892/etm.2024.12765. eCollection 2025 Jan.
4
Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review.史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症与免疫检查点抑制剂相关：系统评价。
Front Immunol. 2024 Jul 12;15:1414136. doi: 10.3389/fimmu.2024.1414136. eCollection 2024.
5
Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.免疫检查点抑制剂诱导的表皮坏死松解症：评估人口统计学、临床特征和罪魁祸首药物的叙述性综述。
J Dermatol. 2024 Jan;51(1):3-11. doi: 10.1111/1346-8138.17039. Epub 2023 Nov 30.
6
Causes of Drug-Induced Severe Cutaneous Adverse Reaction Epidermal Necrolysis (EN): An Analysis Using FDA Adverse Event Reporting System (FAERS) Database.药物性严重皮肤不良反应表皮坏死松解症（EN）的病因：使用美国食品药品监督管理局不良事件报告系统（FAERS）数据库进行的分析
Clin Cosmet Investig Dermatol. 2023 Aug 16;16:2249-2257. doi: 10.2147/CCID.S422928. eCollection 2023.
7
Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review.阿达木单抗治疗信迪利单抗诱导的转移性胃癌患者中毒性表皮坏死松解症：一例报告及文献复习
Clin Cosmet Investig Dermatol. 2023 Feb 20;16:457-461. doi: 10.2147/CCID.S401286. eCollection 2023.
本文引用的文献
1
Immune checkpoint inhibitor-related dermatologic adverse events.免疫检查点抑制剂相关的皮肤不良反应。
J Am Acad Dermatol. 2020 Nov;83(5):1255-1268. doi: 10.1016/j.jaad.2020.03.132. Epub 2020 May 23.
2
Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis.帕博利珠单抗继发大疱性类天疱疮，酷似中毒性表皮坏死松解症。
JAAD Case Rep. 2020 Apr 29;6(5):400-402. doi: 10.1016/j.jdcr.2020.03.003. eCollection 2020 May.
3
Toxic epidermal necrolysis associated with pembrolizumab.与帕博利珠单抗相关的中毒性表皮坏死松解症。
J Oncol Pharm Pract. 2020 Jul;26(5):1259-1265. doi: 10.1177/1078155219890659. Epub 2019 Dec 6.
4
Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients-Exposed/Unexposed and Propensity Score-Matched Analyses.环孢素治疗表皮松解坏死型药疹：在 174 例暴露/未暴露患者的回顾性队列和倾向评分匹配分析中均未观察到获益。
J Invest Dermatol. 2018 Jun;138(6):1293-1300. doi: 10.1016/j.jid.2017.12.034. Epub 2018 Jan 31.
5
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.尼伏鲁单抗单药治疗的安全性概况：晚期黑色素瘤患者的汇总分析。
J Clin Oncol. 2017 Mar;35(7):785-792. doi: 10.1200/JCO.2015.66.1389. Epub 2016 Nov 14.
6
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.抗程序性死亡蛋白1（PD-1）和抗程序性死亡配体1（PD-L1）免疫检查点抗体的毒性。
Ann Oncol. 2015 Dec;26(12):2375-91. doi: 10.1093/annonc/mdv383. Epub 2015 Sep 14.
7
Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.环孢素治疗 Stevens-Johnson 综合征和中毒性表皮坏死松解症的开放试验。
Br J Dermatol. 2010 Oct;163(4):847-53. doi: 10.1111/j.1365-2133.2010.09863.x.
8
SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.SCORTEN：一种中毒性表皮坏死松解症的疾病严重程度评分系统。
J Invest Dermatol. 2000 Aug;115(2):149-53. doi: 10.1046/j.1523-1747.2000.00061.x.
Zotero 插件